Prevymis Disease Interactions

The use of letermovir is not recommended for patients with severe liver dysfunction (Child-Pugh C). No dosage adjustment of letermovir is required for patients with mild or moderate liver dysfunction (Child-Pugh A or B).

Hydroxypropyl betadex present in the IV letermovir formulation is mainly eliminated by glomerular filtration. Decreased elimination of hydroxypropyl betadex has been reported in patients with severe renal dysfunction. Serum creatinine levels should be closely monitored in patients with CrCl less than 50 mL/min using letermovir injection because accumulation of the IV vehicle (hydroxypropyl betadex) could occur. In patients with CrCl greater than 10 mL/min, no dosage adjustment of letermovir is required based on renal dysfunction. The safety of letermovir in patients with end-stage renal disease (CrCl less than 10 mL/min), including patients on dialysis, is unknown.